- £164.18m
- £133.68m
- £74.35m
- 92
- 27
- 63
- 67
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 16.17 | ||
| PEG Ratio (f) | 0.59 | ||
| EPS Growth (f) | 37.72% | ||
| Dividend Yield (f) | 2.14% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.69 | ||
| Price to Tang. Book | 4.13 | ||
| Price to Free Cashflow | 15.69 | ||
| Price to Sales | 2.2 | ||
| EV to EBITDA | 8.56 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 7.55% | ||
| Return on Equity | 5.28% | ||
| Operating Margin | 10.59% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | £m | 71.12 | 70.49 | 74.02 | 71.62 | 74.35 | 74.22 | 91.64 | 0.51% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -5.93 | -40.63 | -41.91 | +53.59 | +5.47 | +91.11 | +37.72 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Animalcare Group plc is a United Kingdom-based international veterinary sales and marketing company. The Company is focused on bringing products to market through its own development pipeline, partnerships and through acquisitions. The Company develops and commercializes prescription and over-the-counter pharmaceutical products that improve animal health and wellbeing. These are developed in-house, acquired from other companies or in-licensed from its partners. The Company manages an international supply chain, including specialist veterinary wholesalers and distributors. It partners with companies to commercialize products across Europe. The Company operates in three categories within the veterinary market: companion animals, equine and other, and production animals. Its product pipeline is Daxocox, which is a differentiated COX-2 inhibitor for the treatment of chronic pain in dogs. The Company operates in seven countries and exports to about 40 countries in Europe and worldwide.
Directors
- Jan Boone NEC (50)
- Jennifer Winter CEO
- Chris Brewster CFO (44)
- Chris Cardon NED
- Marc Coucke NED (56)
- Nick Downshire NID (57)
- Douglas Hutchens NID (58)
- Edwin Torr NID
- Last Annual
- December 31st, 2023
- Last Interim
- June 30th, 2024
- Incorporated
- June 14th, 1972
- Public Since
- January 15th, 2008
- No. of Employees
- 226
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
London Stock Exchange- Shares in Issue
- 68,984,915
- Address
- Moorside, Monks Cross, YORK, YO32 9LB
- Web
- https://www.animalcaregroup.com/
- Phone
- +44 1904487687
- Contact
- Chris Brewster
- Auditors
- PricewaterhouseCoopers LLP
Latest News for ANCR
Upcoming Events for ANCR
Full Year 2024 Animalcare Group plc Analyst Presentation
Full Year 2024 Animalcare Group plc Earnings Release
Full Year 2024 Animalcare Group plc Investor Presentation
Animalcare Group PLC Annual Shareholders Meeting
Half Year 2025 Animalcare Group plc Earnings Release
Similar to ANCR
Alliance Pharma
London Stock Exchange
AstraZeneca
London Stock Exchange
Beximco Pharmaceuticals
London Stock Exchange
BSF Enterprise
London Stock Exchange
Celadon Pharmaceuticals
London Stock Exchange
FAQ
As of Today at 19:15 UTC, shares in Animalcare are trading at 238.00p. This share price information is delayed by 15 minutes.
Shares in Animalcare last closed at 238.00p and the price had moved by +9.68% over the past 365 days. In terms of relative price strength the Animalcare share price has outperformed the FTSE All Share Index by +6.67% over the past year.
The overall consensus recommendation for Animalcare is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreThe Animalcare dividend yield is 2.1% based on the trailing twelve month period.
Last year, Animalcare paid a total dividend of £0.05, and it currently has a trailing dividend yield of 2.1%. We do not have any data on when Animalcare is to next pay dividends.
We do not have data on when Animalcare is to next pay dividends. The historic dividend yield on Animalcare shares is currently 2.1%.
To buy shares in Animalcare you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of 238.00p, shares in Animalcare had a market capitalisation of £164.18m.
Here are the trading details for Animalcare:
- Country of listing: United Kingdom
- Exchange: LSE
- Ticker Symbol: ANCR
Based on an overall assessment of its quality, value and momentum Animalcare is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Animalcare is 323.33p. That is 35.85% above the last closing price of 238.00p.
Analysts covering Animalcare currently have a consensus Earnings Per Share (EPS) forecast of £0.11 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Animalcare. Over the past six months, its share price has outperformed the FTSE All Share Index by +3.43%.
As of the last closing price of 238.00p, shares in Animalcare were trading -1.51% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Animalcare PE ratio based on its reported earnings over the past 12 months is 16.17. The shares last closed at 238.00p.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Animalcare's management team is headed by:
- Jan Boone - NEC
- Jennifer Winter - CEO
- Chris Brewster - CFO
- Chris Cardon - NED
- Marc Coucke - NED
- Nick Downshire - NID
- Douglas Hutchens - NID
- Edwin Torr - NID